

ROTHWELL TIMOTHY G  
Form 3  
June 19, 2009

**FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0104  
Expires: January 31, 2005  
Estimated average burden hours per response... 0.5

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,  
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section  
30(h) of the Investment Company Act of 1940

(Print or Type Responses)

|   |         |          |   |  |   |  |
|---|---------|----------|---|--|---|--|
| 1. Name and Address of Reporting Person *       |         |          | 2. Date of Event Requiring Statement  |  | 3. Issuer Name <b>and</b> Ticker or Trading Symbol  |  |
| Â ROTHWELL TIMOTHY G                            |         |          | (Month/Day/Year)  |  | ANTIGENICS INC /DE/ [agen]  |  |
| (Last)  | (First) | (Middle) | 06/11/2009  |  | 4. Relationship of Reporting Person(s) to Issuer  |  |
| C/O ANTIGENICS INC.,Â 162 FIFTH AVE., SUITE 900 |         |          |   |  | 5. If Amendment, Date Original Filed(Month/Day/Year)  |  |
| (Street)  |         |          |   |  | (Check all applicable)  |  |
| NEW YORK,Â NYÂ 10010                            |         |          |   |  | 6. Individual or Joint/Group Filing(Check Applicable Line)  |  |
| (City)  | (State) | (Zip)    |   |  | <input checked="" type="checkbox"/> Form filed by One Reporting Person<br><input type="checkbox"/> Form filed by More than One Reporting Person |  |
|   |         |          | <input checked="" type="checkbox"/> Director <input type="checkbox"/> 10% Owner<br><input type="checkbox"/> Officer <input type="checkbox"/> Other<br>(give title below)    (specify below) |  |   |  |

**Table I - Non-Derivative Securities Beneficially Owned**

|                                    |  |   |  |
|------------------------------------|--|---|--|
| 1. Title of Security<br>(Instr. 4) | 2. Amount of Securities Beneficially Owned<br>(Instr. 4) | 3. Ownership Form:<br>Direct (D)<br>or Indirect (I)<br>(Instr. 5) | 4. Nature of Indirect Beneficial Ownership<br>(Instr. 5) |
|------------------------------------|--|---|--|

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

**Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

|   |   |  |  |  |  |
|---|---|--|--|--|--|
| 1. Title of Derivative Security<br>(Instr. 4) | 2. Date Exercisable and Expiration Date<br>(Month/Day/Year) | 3. Title and Amount of Securities Underlying Derivative Security<br>(Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form of Derivative Security:<br>Direct (D)<br>or Indirect (I) | 6. Nature of Indirect Beneficial Ownership<br>(Instr. 5) |
|   | Date Exercisable    Expiration Date                         | Title                      Amount or Number of Shares                          |  |  |  |

(Instr. 5)

Stock Option (right to buy) 06/11/2010<sup>(1)</sup> 06/11/2019 Common Stock 25,000 \$ 2.14 D <sup>^</sup>

## Reporting Owners

| Reporting Owner Name / Address   | Relationships  |              |              |              |
|--|----------------|--------------|--------------|--------------|
|  | Director       | 10% Owner    | Officer      | Other        |
| ROTHWELL TIMOTHY G<br>C/O ANTIGENICS INC.<br>162 FIFTH AVE., SUITE 900<br>NEW YORK, NY 10010 | <sup>^</sup> X | <sup>^</sup> | <sup>^</sup> | <sup>^</sup> |

## Signatures

Christine M. Klaskin, by Power of Attorney 06/19/2009  
 \*\*Signature of Reporting Person Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Options vest over three years beginning June 11, 2010.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number. nd 5)6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Underlying Securities (Instr. 3 and 4)8. Price of Derivative Security (Instr. 5)9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)11. Nature of Indirect Beneficial Ownership (Instr. 4)CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares Employee Stock Option (right to buy) \$ 14.7604/27/2015 M 20,478 <sup>(2)</sup>02/08/2022 Common Stock 20,478 \$ 0 6,828 <sup>(2)</sup> D

## Reporting Owners

| Reporting Owner Name / Address  | Relationships |           |                          |       |
|---|---------------|-----------|--------------------------|-------|
|   | Director      | 10% Owner | Officer                  | Other |
| FERGUSON STANLEY L<br>C/O USG CORPORATION<br>550 W. ADAMS STREET<br>CHICAGO, IL 60661 |               |           | Executive Vice President |       |

## Signatures

/s/ Jessica A. Garascia, Attorney-In-Fact 04/29/2015  
 \*\*Signature of Reporting Person Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) The per share sale price for the common stock sold in the reported transaction ranged from \$28.00 to \$28.43. The reporting person will provide upon request by the Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares sold at each separate price.

(2) The option vested with respect to the shares included in the reported transaction in three equal annual installments beginning on February 8, 2013. As of the date of this report 6,828 options remain outstanding.

(3) The per share sales price for the common stock sold in the reported transaction ranged from \$27.95 to \$28.26. The reporting person will provide upon request by the Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares sold at each separate price.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.